A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

July 2, 2024

Study Completion Date

December 31, 2029

Conditions
HIV Infection
Interventions
DRUG

Teropavimab

Administered intravenously

DRUG

Zinlirvimab

Administered intravenously

DRUG

Lenacapavir Tablet

Administered orally

DRUG

Lenacapavir Injection

Administered subcutaneously

DRUG

Antiretroviral Therapy

Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.

Trial Locations (34)

909

Clinical Research Puerto Rico, San Juan

2010

East Sydney Doctors, Darlinghurst

3004

Alfred Hospital, Melbourne

10467

Montefiore Medical Center, The Bronx

20007

Georgetown University Medical Center, Washington D.C.

22003

Clinical Alliance for Research & Education, Infectious Diseases LLC (CARE-ID), Annandale

27401

Regional Center for Infectious Disease Research, Greensboro

27514

NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke University Health Center, Durham

27858

The Brody School of Medicine at East Carolina University, Greenville

28078

Rosedale Health and Wellness, Huntersville

29203

Prisma Health - Clinical Research Unit, Columbia

30033

Infectious Disease Specialists of Atlanta, Decatur

30308

Emory University Hospital Midtown Infectious Disease Clinic, Atlanta

32720

Midland Florida Clinical Research Center, LLC, DeLand

32803

Orlando Immunology Center, Orlando

33316

Can Community Health Care, Fort Lauderdale

33407

Triple O Research Institute, P.A., West Palm Beach

34982

Midway Immunology and Research Center, Ft. Pierce

38105

St Jude Children's Research Hospital, Memphis

63139

Southhampton Healthcare, Inc, St Louis

75208

AIDS Arms, Inc. DBA Prism Health North Texas, Dallas

77098

The Crofoot Research Center, INC, Houston

78705

Central Texas Clinical Research, Austin

79902

AXCES Research Group, LLC, El Paso

80045

University of Colorado Clinical and Translational Research Center, Aurora

87109

AXCES Research Group, LLC, Albuquerque

90036

Ruane Clinical Research Group, Inc., Los Angeles

90069

Mills Clinical Research, Los Angeles

92103

UC San Diego (UCSD) AntiViral Research Center (AVRC), San Diego

94102

Optimus Medical Group, San Francisco

06510

Yale University; School of Medicine; AIDS Program, New Haven

2010 NSW

Holdsworth House Medical Practice, Sydney

M5G 1K2

Maple Leaf Research/Maple Leaf Medical Clinic, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT05729568 - A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection | Biotech Hunter | Biotech Hunter